{"id":1602,"date":"2024-12-18T09:05:30","date_gmt":"2024-12-18T09:05:30","guid":{"rendered":"https:\/\/minervainstitute.fi\/minervastiftelsens-symposium-2025\/"},"modified":"2025-01-31T09:25:34","modified_gmt":"2025-01-31T09:25:34","slug":"minervastiftelsens-symposium-2025","status":"publish","type":"post","link":"https:\/\/minervainstitute.fi\/sv\/minervastiftelsens-symposium-2025\/","title":{"rendered":"Minervastiftelsens Symposium 2025"},"content":{"rendered":"<h4>FROM GENETIC OBSERVATIONS TO FUNCTIONAL INSIGHT AND THERAPY DEVELOPMENT<\/h4>\n<p>Oktober 23 \u2013 24, 2025, Hanaholmen, Esbo, Finland<\/p>\n<pre>Note. Tentative program, subject to change.<\/pre>\n<p><a href=\"https:\/\/minervainstitute.fi\/wp-content\/uploads\/2024\/12\/Minerva-Foundation-Symposium-2025_program.pdf\">Minerva Foundation Symposium 2025_program<\/a><\/p>\n<p>SESSION I<\/p>\n<p><strong><em>Steatotic liver disease \u2013 Leveraging genetics for therapeutic insights<\/em><\/strong><\/p>\n<p><strong>Panu Luukkonen<\/strong>, Minerva Foundation Institute for medical Research<br \/>\n<em>Hepatic mitochondrial reductive stress \u2013 from genetics via bench to bedside<\/em><\/p>\n<p><strong>Russell Goodman<\/strong>, Harvard\/Massachusetts General Hospital, USA<br \/>\n<em>Reductive stress in steatotic liver disease \u2013 focus on GCKR<\/em><\/p>\n<p><strong>Shawn Burgess<\/strong>, UT Southwestern, USA<br \/>\n<em>Intermediary metabolism in steatotic liver disease \u2013 focus on ACC<\/em><\/p>\n<p><strong>Sami Qadri<\/strong>, Minerva Foundation Institute for medical Research<br \/>\n<em>Functional characterization of protective gene variants in steatotic liver disease<\/em><\/p>\n<p>SESSION II<\/p>\n<p><strong><em>Incretins \u2013 Bench to bedside<\/em><\/strong><\/p>\n<p><strong>Petter Bjornstad<\/strong>, University of Washington, Seattle, USA<br \/>\n<em>Incretins &#8211; Gut to brain and back<\/em><\/p>\n<p><strong>David Cherney<\/strong>, University of Toronto, Canada<br \/>\n<em>Incretins in patients with type 1 diabetes<\/em><\/p>\n<p><strong>Ian de Boer<\/strong>, University of Washington, Seattle, USA<br \/>\n<em>Incretins in the kidney guidelines 2027<\/em><\/p>\n<p>SESSION III<\/p>\n<p><em><strong>Bone and mineral metabolism, its genetic components and therapeutic approaches<\/strong> <\/em><\/p>\n<p><strong>Wim van Hul, University of Antwerp, Belgium<br \/>\n<\/strong><em>The road from the discovery of sclerostin mutations to clinical applications<\/em><\/p>\n<p><strong>Harald J\u00fcppner<\/strong>, Massachusetts General Hospital, Harvard Medical School, Boston, USA<br \/>\n<em>The clinical landscape of parathormone signaling<\/em><\/p>\n<p><strong>Outi M\u00e4kitie<\/strong>, Folkh\u00e4lsan, University of Helsinki and Helsinki University Hospital<br \/>\n<em>Monogenic osteoporosis \u2013 lessons from rare phenotypes to population health problems<\/em><\/p>\n<p><strong>Heikki Koistinen<\/strong>, Minerva Foundation Institute for Medical Research<br \/>\n<em>Kidney stone disease and genetics of hypercalciuria<\/em><\/p>\n<p>SESSION IV<\/p>\n<p><strong><em>Genetics and pharmacogenetics in personalized medicine<\/em><\/strong><\/p>\n<p><strong>Hanna Ollila<\/strong>, FIMM, University of Helsinki and Stanford University, CA, USA<br \/>\n<em>Genetic and functional analysis of Raynaud\u2019s syndrome implicates loci in vasculature and immunity<\/em><\/p>\n<p><strong>Adrian Krainer<\/strong>, Cold Spring Harbor Laboratory, NY, USA<br \/>\n<em>Splicing defect as a cause of spinal muscular atrophy (SMA): Therapy with a splicing-correcting antisense oligonucleotide<\/em><\/p>\n<p><strong>Mikko Niemi<\/strong>, University of Helsinki<br \/>\n<em>Pharmacogenetics in personalized medicine<\/em><\/p>\n<p><strong>Elisabeth Widen<\/strong>, FIMM, University of Helsinki<br \/>\n<em>Inherited infertility &#8211; mapping loci associated with impaired female reproduction<\/em><\/p>\n<p>PANEL DISCUSSION<\/p>\n<p><strong><em>Expensive new therapies: who invented, who profits, who can afford?<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FROM GENETIC OBSERVATIONS TO FUNCTIONAL INSIGHT AND THERAPY DEVELOPMENT Oktober  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-1602","post","type-post","status-publish","format-standard","hentry","category-okategoriserad"],"_links":{"self":[{"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/posts\/1602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/comments?post=1602"}],"version-history":[{"count":2,"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/posts\/1602\/revisions"}],"predecessor-version":[{"id":1636,"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/posts\/1602\/revisions\/1636"}],"wp:attachment":[{"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/media?parent=1602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/categories?post=1602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/minervainstitute.fi\/sv\/wp-json\/wp\/v2\/tags?post=1602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}